--- title: "Beigene (6160.HK): Range-bound fluctuations, cautious and repeated capital, the game in the pharmaceutical sector becomes complex before new regulations" description: "On February 3rd, BeiGene experienced significant fluctuations throughout the day, opening high and then pulling back. Although funds were somewhat active in the short term, supporting a slight rebound" type: "news" locale: "en" url: "https://longbridge.com/en/news/274628892.md" published_at: "2026-02-04T01:00:00.000Z" --- # Beigene (6160.HK): Range-bound fluctuations, cautious and repeated capital, the game in the pharmaceutical sector becomes complex before new regulations > On February 3rd, BeiGene experienced significant fluctuations throughout the day, opening high and then pulling back. Although funds were somewhat active in the short term, supporting a slight rebound, the overall trend showed weakness. Currently, the pharmaceutical sector is relatively mild, with some long-term funds testing the waters as the market rebounds. The main operators displayed clear hesitation and repetition, with the day's rhythm primarily characterized by strong fluctuations. Recently, the market has focused on news such as "new contracts in the CXO business," which has activated short-term funds related to pharmaceuticals. However, despite increased trading volume, the main funds are still primarily engaged in range trading, leading to intensified overall bullish-bearish divergence and a strong wait-and-see atmosphere. The MACD daily signal has shown some phase repair, but the pressure from the unblocking area above the stock price and long-term resistance remains heavy, with no clear signs of sustained upward movement from the main operators. On the news front, there are currently no major disturbances in the pharmaceutical sector, and the rotation of themes and active funds has revealed structural opportunities. The intraday performance showed a high opening and pullback, with multiple tests of the 20-day line, where right-side funds dominated the intraday game. However, the volume cooperation is limited, constraining the rebound space, and the signals from large orders are scattered. Overall, a new round of regulatory details for the pharmaceutical industry is about to be released, becoming a key focus for the market and significantly impacting the sector's trend. The risk exposure cannot be ignored; if negative news arises or if the main operators significantly reduce their holdings, the pressure will intensify. It is recommended to continue monitoring policy dynamics and changes in hotspots within the pharmaceutical sector, dynamically managing positions to cope with uncertainties On February 3rd, BeiGene experienced significant fluctuations throughout the day, opening high and then pulling back. Although funds were somewhat active in the short term, supporting a slight rebound, the overall trend showed a lack of follow-through strength. Currently, the pharmaceutical sector is relatively mild, with some long-term funds testing the waters as the market rebounds. The main operators displayed clear hesitation and repetition, with the day's rhythm primarily characterized by strong fluctuations. Recently, the market has focused on news such as "new contracts flowing out of the CXO business," which has activated short-term funds related to pharmaceuticals. However, despite an increase in trading volume, the main funds are still primarily engaged in range trading, leading to intensified overall bullish-bearish divergence and a strong wait-and-see atmosphere. The MACD daily signal has shown some phase repair, but the resistance zone above the stock price and long-term pressure remain heavy, with no clear signs of sustained upward movement from the main operators. On the news front, there are currently no major disturbances in the pharmaceutical sector. The rotation of themes and active funds have revealed structural opportunities. The intraday performance showed a high opening and pullback, with multiple tests of the 20-day moving average. Right-side funds dominated the intraday game, but the volume cooperation was limited, constraining the rebound space, and the signals from large orders were scattered. Overall, a new round of regulatory details for the pharmaceutical industry is about to be released, becoming a key focus for the market and significantly impacting the sector's trend. The risk exposure cannot be ignored; if negative news arises or the main operators significantly reduce their holdings, the pressure will intensify. It is recommended to continue monitoring policy dynamics and changes in hotspots within the pharmaceutical sector, dynamically managing positions to cope with uncertainties ### Related Stocks - [06160.HK - BEONE MEDICINES](https://longbridge.com/en/quote/06160.HK.md) - [688235.CN - BeOne Medicines](https://longbridge.com/en/quote/688235.CN.md) - [BGNE.US - Beigene](https://longbridge.com/en/quote/BGNE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost | U.S. FDA Commissioner Marty Makary stated that while the FDA supports mRNA vaccines, taxpayers should not bear the costs | [Link](https://longbridge.com/en/news/276639643.md) | | Cruise operators alter Mexico routes amid cartel unrest | Major U.S. cruise operators are altering their routes in Mexico due to violence following the killing of cartel leader N | [Link](https://longbridge.com/en/news/276727006.md) | | Cruise companies cancel Puerto Vallarta stops after violence in Mexico | American cruise companies are rerouting ships and managing tourist safety in Mexico following violence after the killing | [Link](https://longbridge.com/en/news/276654433.md) | | Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics | Stoke Therapeutics (NASDAQ:STOK) received mixed ratings from 5 analysts over the past three months, with an average 12-m | [Link](https://longbridge.com/en/news/276737858.md) | | Gossamer Bio reports topline Phase III PROSERA outcomes for PAH | Gossamer Bio has reported topline results from the Phase III PROSERA study of seralutinib for pulmonary arterial hyperte | [Link](https://longbridge.com/en/news/276722856.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.